HaplnScience
Latest round
- Series B
Last raised
- Jan 2021
Total raised
- $29M
Investors
- 10
About HaplnScience
HaplnScience, Inc. was founded in 2018 and operates out of Seongnam, South Korea. The company is engaged in creating advanced therapies for conditions such as chronic obstructive pulmonary disease (COPD) and osteoarthritis (OA).HaplnScience specializes in advanced regenerative medicine therapies targeting anti-aging and tissue regeneration. Their product lineup includes HS-401 for COPD, HS-101 for osteoarthritis, HS-601 for dry eye disease, HS-201 for skin aging, and HS-301 addressing hair loss, utilizing unique delivery methods like inhalation and injections to enhance patient care.HaplnScience generates revenue through direct sales of its therapeutic products to healthcare institutions, supplemented by potential partnerships with pharmaceutical firms. The company handles bulk orders from medical facilities, supported by training for healthcare professionals. Pricing is determined by the complexity of therapies, ensuring tailored solutions for healthcare providers.In January 2021, HaplnScience, Inc. The company plans to introduce new products targeting unmet medical needs and is looking to expand into additional markets in North America and Europe by 2023.
Who invested in HaplnScience
10 investors across 4 rounds
See all investors in HaplnScience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about HaplnScience
Who invested in HaplnScience?
HaplnScience has 10 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has HaplnScience raised?
HaplnScience has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did HaplnScience last raise money?
HaplnScience's most recent round on record is a Series B, in Jan 2021.
What does HaplnScience do?
HaplnScience is a pharmaceuticals company.
Where is HaplnScience headquartered?
HaplnScience is headquartered in Seongnam, South Korea.
Which VCs invest in companies like HaplnScience?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at HaplnScience's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like HaplnScience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.